A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

Exclusion Criteria

• •Known history of Hib infection, HepB, diphtheria, tetanus, pertussis, or poliomyelitis
• •Household contact or intimate exposure with a confirmed case of Hib, HepB, diphtheria, pertussis, tetanus or poliomyelitis within 30 days prior to study registration
• •Known history of SARS-CoV-2 infection
• •Participant's mother is HepB antigen or HIV positive
• •Fever ≥ 38.0 C/100.4 F within 3 days prior to enrollment
• •Vaccination history of non-study vaccines within 30 days prior to enrollment except for pneumococcal conjugate, rotavirus, HepB and Bacillus Calmette Guerin (BCG)
• •Previous use of any diphtheria, tetanus, pertussis-based combination vaccine(s), Hib conjugate, poliovirus, or combination
• •Received immunosuppressive agents or other immune-modifying drugs
• •Previous use of blood or blood-derived products
• •Any history of allergy (hypersensitivity) to any of the vaccine components
• •Participation in another interventional clinical trial within 4 weeks of expected first vaccination